http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 17:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26667032.html si-local-file:///var/storage/secattach/20260618/26667032.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26667032.html Thu, 18 Jun 2026 17:00:00 -0400 O.00178515 UCB http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26667032.html si-local-file:///var/storage/secattach/20260618/26667032.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26667032.html Thu, 18 Jun 2026 17:00:00 -0400 O.00178515 UCB http://www.streetinsider.com/Analyst+PT+Change/United+Community+Banks+%28UCB%29+PT+Lowered+at+Piper+Sandler+Following+Navitas+Sale/26656588.html (Updated - June 17, 2026 7:52 AM EDT) <p>Piper Sandler analyst Stephen Scouten lowered the price target on United Community Banks (NYSE: UCB) to $35.00 (from $36.00) while maintaining a Neutral rating.</p><p>The analyst commented: "Updating our Model to Account for the Navitas Sale - Last week, UCB announced that it is selling its Navitas Credit Corp equipment finance subsidiary. In total, this sale should drive a ~$109M pre-tax benefit, or ~$0.67 to TBVPS, and is estimated to be ~9% dilutive to run-rate earnings in the immediate term. In the near/medium-term, UCB will work to redeploy the ~$1.9B in new liquidity (initially http://www.streetinsider.com/Analyst+PT+Change/United+Community+Banks+%28UCB%29+PT+Lowered+at+Piper+Sandler+Following+Navitas+Sale/26656588.html Wed, 17 Jun 2026 07:52:53 -0400 UCB http://www.streetinsider.com/Analyst+Comments/United+Community+Banks+%28UCB%29+PT+Lowered+at+Piper+Sandler+Following+Navitas+Sale/26656588.html (Updated - June 17, 2026 7:52 AM EDT) <p>Piper Sandler analyst Stephen Scouten lowered the price target on United Community Banks (NYSE: UCB) to $35.00 (from $36.00) while maintaining a Neutral rating.</p><p>The analyst commented: "Updating our Model to Account for the Navitas Sale - Last week, UCB announced that it is selling its Navitas Credit Corp equipment finance subsidiary. In total, this sale should drive a ~$109M pre-tax benefit, or ~$0.67 to TBVPS, and is estimated to be ~9% dilutive to run-rate earnings in the immediate term. In the near/medium-term, UCB will work to redeploy the ~$1.9B in new liquidity (initially http://www.streetinsider.com/Analyst+Comments/United+Community+Banks+%28UCB%29+PT+Lowered+at+Piper+Sandler+Following+Navitas+Sale/26656588.html Wed, 17 Jun 2026 07:52:53 -0400 UCB http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/Press+Releases/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html <div class="xn-content"> <ul type="disc"><li>Data indicate that KYGEVVI therapy improved survival and functional outcomes in people with TK2d.¹</li><li>Additional data from the largest pool of information on TK2d illustrates the impact and burden of disease progression² and highlights the benefits of early diagnosis.³</li></ul><p><span class="legendSpanClass"><location value="LU/us.ga.atlnta" idsrc="xmltag.org" >ATLANTA</location></span>, <span class="legendSpanClass"><chron>June 17, 2026</chron></span> /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of two manuscripts in <i><span>Brain Communications</span></i>. One manuscript reports integrated safety and efficacy findings for KYGEVVI^® (doxecitine and doxribtimine), the first and only approved treatment for adults and pediatric patients with early-onset thymidine kinase 2 deficiency (TK2d) with a symptom onset on http://www.streetinsider.com/PRNewswire/UCB+Announces+Publication+of+Data+in+Brain+Communications+Demonstrating+Positive+Impact+of+KYGEVVI%C2%AE+%28doxecitine+and+doxribtimine%29+in+Patients+with+Thymidine+Kinase+2+Deficiency+%28TK2d%29/26656699.html Wed, 17 Jun 2026 07:00:00 -0400 A.06822034 A.31066700 O.19039711 O.20026344 O.22422661 UCB UCBJY http://www.streetinsider.com/Analyst+PT+Change/United+Community+Banks+%28UCB%29+PT+Raised+to+%2440+at+DA+Davidson+on+Navitas+Sale/26645184.html <p>DA Davidson analyst Gary Tenner raised the price target on United Community Banks (NYSE: UCB) to $40.00 (from $39.00) while maintaining a Buy rating.</p><p>The analyst commented, "We view UCB's sale of its Navitas equipment finance business as a net positive for the company over the medium-to-long term, as it eliminates a non-core part of the regional banking story, that had driven an outsized proportion of its NCOs. The decision to sell also highlights management's increasing confidence in its ability to accelerate loan growth, particularly in 2027, as 38 production hires made since September 30, 2025 ramp growth in the second http://www.streetinsider.com/Analyst+PT+Change/United+Community+Banks+%28UCB%29+PT+Raised+to+%2440+at+DA+Davidson+on+Navitas+Sale/26645184.html Mon, 15 Jun 2026 09:18:01 -0400 UCB http://www.streetinsider.com/Analyst+Comments/United+Community+Banks+%28UCB%29+PT+Raised+to+%2440+at+DA+Davidson+on+Navitas+Sale/26645184.html <p>DA Davidson analyst Gary Tenner raised the price target on United Community Banks (NYSE: UCB) to $40.00 (from $39.00) while maintaining a Buy rating.</p><p>The analyst commented, "We view UCB's sale of its Navitas equipment finance business as a net positive for the company over the medium-to-long term, as it eliminates a non-core part of the regional banking story, that had driven an outsized proportion of its NCOs. The decision to sell also highlights management's increasing confidence in its ability to accelerate loan growth, particularly in 2027, as 38 production hires made since September 30, 2025 ramp growth in the second http://www.streetinsider.com/Analyst+Comments/United+Community+Banks+%28UCB%29+PT+Raised+to+%2440+at+DA+Davidson+on+Navitas+Sale/26645184.html Mon, 15 Jun 2026 09:18:01 -0400 UCB http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26639232.html si-local-file:///var/storage/secattach/20260612/26639232.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26639232.html Fri, 12 Jun 2026 10:48:00 -0400 O.00178515 UCB http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26639232.html si-local-file:///var/storage/secattach/20260612/26639232.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++UNITED+COMMUNITY+BANKS+++++++++++++++++Filed+by%3A+UNITED+COMMUNITY+BANKS+INC/26639232.html Fri, 12 Jun 2026 10:48:00 -0400 O.00178515 UCB http://www.streetinsider.com/Mergers+and+Acquisitions/Wafra+to+acquire+Navitas+Credit+for+%241.9+billion+from+United+Community/26638832.html <p>Wafra Inc., a $30 billion New York-based alternative asset manager, announced that its investment funds have entered into a definitive agreement to acquire Navitas Credit Corp. from United Community Bank for approximately $1.9 billion in cash.</p> <p>United Community Bank is a wholly-owned subsidiary of United Community Banks, Inc. (NYSE: UCB). The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.</p> <p>Navitas, founded in 2008 and headquartered in Ponte Vedra, Florida, specializes in financing equipment purchases for small and mid-sized businesses. The company operates nationally with more than 200 employees across six locations and had $1.8 http://www.streetinsider.com/Mergers+and+Acquisitions/Wafra+to+acquire+Navitas+Credit+for+%241.9+billion+from+United+Community/26638832.html Fri, 12 Jun 2026 09:21:39 -0400 A.05850503 A.07735644 A.07937850 A.29917926 A.39420645 A.50202048 A.50213524 O.00047990 O.00178515 O.03616677 O.03960845 O.05908838 O.32241120 O.38259977 O.39003587 UCB http://www.streetinsider.com/Mergers+and+Acquisitions/Wafra+to+acquire+Navitas+Credit+for+%241.9+billion+from+United+Community/26638832.html <p>Wafra Inc., a $30 billion New York-based alternative asset manager, announced that its investment funds have entered into a definitive agreement to acquire Navitas Credit Corp. from United Community Bank for approximately $1.9 billion in cash.</p> <p>United Community Bank is a wholly-owned subsidiary of United Community Banks, Inc. (NYSE: UCB). The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.</p> <p>Navitas, founded in 2008 and headquartered in Ponte Vedra, Florida, specializes in financing equipment purchases for small and mid-sized businesses. The company operates nationally with more than 200 employees across six locations and had $1.8 http://www.streetinsider.com/Mergers+and+Acquisitions/Wafra+to+acquire+Navitas+Credit+for+%241.9+billion+from+United+Community/26638832.html Fri, 12 Jun 2026 09:21:39 -0400 A.05850503 A.07735644 A.07937850 A.29917926 A.39420645 A.50202048 A.50213524 O.00047990 O.00178515 O.03616677 O.03960845 O.05908838 O.32241120 O.38259977 O.39003587 UCB http://www.streetinsider.com/Mergers+and+Acquisitions/Wafra+to+acquire+Navitas+Credit+for+%241.9+billion+from+United+Community/26638832.html <p>Wafra Inc., a $30 billion New York-based alternative asset manager, announced that its investment funds have entered into a definitive agreement to acquire Navitas Credit Corp. from United Community Bank for approximately $1.9 billion in cash.</p> <p>United Community Bank is a wholly-owned subsidiary of United Community Banks, Inc. (NYSE: UCB). The transaction is expected to close in the third quarter of 2026, subject to customary closing conditions.</p> <p>Navitas, founded in 2008 and headquartered in Ponte Vedra, Florida, specializes in financing equipment purchases for small and mid-sized businesses. The company operates nationally with more than 200 employees across six locations and had $1.8 http://www.streetinsider.com/Mergers+and+Acquisitions/Wafra+to+acquire+Navitas+Credit+for+%241.9+billion+from+United+Community/26638832.html Fri, 12 Jun 2026 09:21:39 -0400 A.05850503 A.07735644 A.07937850 A.29917926 A.39420645 A.50202048 A.50213524 O.00047990 O.00178515 O.03616677 O.03960845 O.05908838 O.32241120 O.38259977 O.39003587 UCB